◎ Sugi Atlas

Atlas / Drug / Cyclosporine

Cyclosporine

drug
On this page

Also known as ANTIBIOTIC S-7481F1AtopicaCapimuneCapsorinCequaCiclosporinCiclosporin aCiclosporinaCiclosporineCiclosporinumCyclosporinCyclosporin aCyclosporine aCyclosporine microemulsionmodifiedDeximuneEquoralGengrafIkervis

Summary

Cyclosporine (CHEMBL160) is an approved protein antifungal agent (ATC S01XA18) targeting SLCO1B1, SLCO1B3, and FPR1; indicated across 133 conditions including psoriasis and immune system disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: S01XA18 (+1 more)
  • Targets: 7 (SLCO1B1, SLCO1B3, FPR1…)
  • Indications: 133 conditions
  • Clinical trials: 642
  • Chemistry: 1202.6 Da · C62H111N11O12

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL160
NameCyclosporine
TypeProtein
Max phase4
FDA approvedyes
PubChem CID5284373
ChEBICHEBI:4031
ATCS01XA18, L04AD01
Molecular formulaC62H111N11O12
Molecular weight1202.6
InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N

SMILES: CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C

IUPAC name: (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone

ChEBI definition: A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient’s immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.

Pharmacological roles (ChEBI): antifungal agent, antirheumatic drug, dermatologic drug, immunosuppressive agent, carcinogenic agent, anti-asthmatic drug, EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor, anticoronaviral agent, geroprotector.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: ANTIBIOTIC S-7481F1, Atopica, Capimune, Capsorin, Cequa, Ciclosporin, Ciclosporin a, Ciclosporina, Ciclosporine, Ciclosporinum, Cyclosporin, Cyclosporin a

Patent coverage: 44,532 distinct patent families (168,247 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SLCO1B1OATP1B1Inhibition7.290%Q9Y6L6
SLCO1B3OATP1B3Inhibition6.10%Q9NPD5
FPR1FPR1Antagonist6.30%P21462
PPIApeptidylprolyl isomerase AInhibition7.7680%P62937
PPIDpeptidylprolyl isomerase DInhibition80.1%Q08752
ABCG2ABCG2Inhibition6.30.1%Q9UNQ0
SLC10A1Sodium/bile acid and sulphated solute cotransporter 1Inhibition5.120.1%Q14973

Broader ChEMBL bioactivity targets: 56 (assay-derived). Sample: Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, Survival motor neuron protein, Prelamin-A/C, RecQ-like DNA helicase BLM, Ferritin light chain, NPC intracellular cholesterol transporter 1, Geminin, Endonuclease 4, Peripheral myelin protein 22.

Bioactivity

ChEMBL activities: 208 potent at pChembl ≥ 5 of 235 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PPIA8.82Ki1.5nMCHEMBL_ACT_26930158
PPIA8.7IC502nMCHEMBL_ACT_613788
PPID8.59Ki2.58nMCHEMBL_ACT_16584541
PPIA8.58Ki2.64nMCHEMBL_ACT_3388832
PPID8.44IC503.6nMCHEMBL_ACT_16584539
PPIA8.43IC503.7nMCHEMBL_ACT_3397089
PPP3CA8.4Kd4nMCHEMBL_ACT_185493
PPIF8.3Ki5nMCHEMBL_ACT_29064090
P043518.3IC505nMCHEMBL_ACT_64919
FKBP1B8.22Ki6nMCHEMBL_ACT_1023967
PPIA8.22Kd6nMCHEMBL_ACT_25072959
PPIA8.17Ki6.7nMCHEMBL_ACT_17956133
PPIA8.15Ki7nMCHEMBL_ACT_24864744
PPID8.15Ki7nMCHEMBL_ACT_5293745
PPIA8.14IC507.2nMCHEMBL_ACT_16437268
PPIA8.12Kd7.6nMCHEMBL_ACT_7850159
PPID8.09Ki8.2nMCHEMBL_ACT_16576386
PPIA8.08IC508.33nMCHEMBL_ACT_3520915
PPIB8.06IC508.78nMCHEMBL_ACT_3520935
PPIA8.05IC509nMCHEMBL_ACT_287452
PPIA8.05Ki9nMCHEMBL_ACT_29064081
PPIA8.05Kd9nMCHEMBL_ACT_3397091
PPIA8.03IC509.3nMCHEMBL_ACT_7850162
PPIA8.02IC509.6nMCHEMBL_ACT_14526331
PPIA8.01IC509.7nMCHEMBL_ACT_17697784
PPIB8.01Kd9.8nMCHEMBL_ACT_2451861
PPIA8.01Ki9.79nMCHEMBL_ACT_5294576
PPIA8Kd10nMCHEMBL_ACT_12204722
PPIA8Kd10nMCHEMBL_ACT_12204723
PPIA8Kd10nMCHEMBL_ACT_12204724

Target pathways

Aggregated over 7 target gene(s): SLCO1B1, SLCO1B3, FPR1, PPIA, PPID, ABCG2, SLC10A1.

Top Reactome pathways

54 total, by targets touching each:

PathwayTargetsGenes
Metabolism3ABCG2, SLCO1B1, SLCO1B3
Recycling of bile acids and salts3SLC10A1, SLCO1B1, SLCO1B3
Metabolism of porphyrins3ABCG2, SLCO1B1, SLCO1B3
Heme degradation3ABCG2, SLCO1B1, SLCO1B3
Transport of small molecules3ABCG2, SLCO1B1, SLCO1B3
Metabolism of lipids3ABCG2, SLCO1B1, SLCO1B3
Drug ADME3ABCG2, SLCO1B1, SLCO1B3
Disease2SLCO1B1, SLCO1B3
Bile acid and bile salt metabolism2SLCO1B1, SLCO1B3
Transport of vitamins, nucleosides, and related molecules2SLCO1B1, SLCO1B3
SLC-mediated transmembrane transport2SLCO1B1, SLCO1B3
SLC transporter disorders2SLCO1B1, SLCO1B3
Disorders of transmembrane transporters2SLCO1B1, SLCO1B3
Neutrophil degranulation2FPR1, PPIA
Organic anion transport by SLCO transporters2SLCO1B1, SLCO1B3
Metabolism of steroids2SLCO1B1, SLCO1B3
Atorvastatin ADME2SLCO1B1, SLCO1B3
Platelet degranulation1PPIA
Developmental Biology1ABCG2
Uncoating of the HIV Virion1PPIA
Budding and maturation of HIV virion1PPIA
Integration of provirus1PPIA
Early Phase of HIV Life Cycle1PPIA
Minus-strand DNA synthesis1PPIA
Plus-strand DNA synthesis1PPIA
Sphingolipid de novo biosynthesis1ABCG2
Binding and entry of HIV virion1PPIA
Assembly Of The HIV Virion1PPIA
APOBEC3G mediated resistance to HIV-1 infection1PPIA
Heme biosynthesis1ABCG2

Dominant GO biological processes

GO termTargets
lipid transport4
transmembrane transport4
monoatomic ion transport3
obsolete organic anion transport3
bile acid and bile salt transport3
xenobiotic metabolic process2
heme catabolic process2
sodium-independent organic anion transport2
protein peptidyl-prolyl isomerization2
protein folding2
apoptotic process2
viral release from host cell2
lipid droplet organization2
positive regulation of viral genome replication2
positive regulation of protein secretion2

Indications & clinical

Indications

133 indications (9 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
psoriasis4MONDO:0005083EFO:0000676
immune system disorder4MONDO:0005046EFO:0000540
rheumatoid arthritis4MONDO:0008383EFO:0000685
eye disorder4MONDO:0005328EFO:0003966
keratoconjunctivitis4MONDO:0004768MONDO:0004768
corneal disorder4MONDO:0000942EFO:0009464
keratitis4MONDO:0003085EFO:0009449
conjunctivitis4MONDO:0003799EFO:0009450
atopic eczema3MONDO:0004980EFO:0000274
lymphoma3MONDO:0005062EFO:0000574
aplastic anemia3MONDO:0015909HP:0001915
myelodysplastic syndrome3MONDO:0018881EFO:0000198
graft versus host disease3MONDO:0013730EFO:0004599
myocardial infarction3MONDO:0005068EFO:0000612
focal segmental glomerulosclerosis3MONDO:0100313EFO:0004236
membranous glomerulonephritis3MONDO:0005376EFO:0004254
dry eye syndrome3MONDO:0006733EFO:1000906
chronic kidney disease3MONDO:0005300EFO:0003884
atopic conjunctivitis3MONDO:0005642EFO:0007141
chronic hepatitis C virus infection3MONDO:0005354EFO:0004220
acute myeloid leukemia3MONDO:0018874EFO:0000222
autoimmune thrombocytopenic purpura3MONDO:0008558EFO:0007160
bronchiolitis obliterans syndrome3MONDO:0015265EFO:0007183
hepatocellular carcinoma3MONDO:0007256EFO:0000182
Hodgkins lymphoma3MONDO:0004952EFO:0000183
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
chronic myeloid leukemia3MONDO:0011996EFO:0000339
juvenile dermatomyositis3MONDO:0008054EFO:0000557
leukemia3MONDO:0005059EFO:0000565
plasma cell myeloma3MONDO:0009693EFO:0001378
heart disorder3MONDO:0005267EFO:0003777
Stevens-Johnson syndrome3MONDO:0018229EFO:0004276
autoimmune hepatitis3MONDO:0016264EFO:0005676
lupus nephritis3MONDO:0005556EFO:0005761
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
Waldenstrom macroglobulinemia3MONDO:0100280EFO:0009441
cardiac arrest3MONDO:0000745EFO:0009492
mantle cell lymphoma3MONDO:0018876EFO:1001469
kidney failure3MONDO:0001106EFO:1002048
kidney disorder3MONDO:0005240EFO:0003086
pure red-cell aplasia3MONDO:0001705MONDO:0001705
skin neoplasm3MONDO:0002531MONDO:0002898
breast neoplasm3MONDO:0021100MONDO:0007254
thrombotic thrombocytopenic purpura3MONDO:0018896MONDO:0018896
Behcet disease3MONDO:0007191EFO:0003780
retinal vasculitis3MONDO:0006950EFO:1001156
acute myocardial infarction3MONDO:0004781EFO:0008583
autoimmune hemolytic anemia3MONDO:0020108EFO:1001264
type 1 diabetes mellitus3MONDO:0005147MONDO:0005147
membranoproliferative glomerulonephritis3MONDO:0002461MONDO:0018904
colorectal neoplasm3MONDO:0005335MONDO:0005575
hepatitis C virus infection2MONDO:0005231EFO:0003047
pterygium2MONDO:0005085EFO:0000678
leprosy2MONDO:0005124EFO:0001054
diabetes mellitus2MONDO:0005015EFO:0000400
periodontitis2MONDO:0005076EFO:0000649
abdominal aortic aneurysm2MONDO:0005350EFO:0004214
acute kidney injury2MONDO:0002492HP:0001919
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
cutaneous melanoma2MONDO:0005012EFO:0000389
neoplasm2MONDO:0005070EFO:0000616
neuroblastoma2MONDO:0005072EFO:0000621
sarcoma2MONDO:0005089EFO:0000691
HIV infectious disease2MONDO:0005109EFO:0000764
liver disorder2MONDO:0005154EFO:0001421
lymphoid neoplasm2MONDO:0005157EFO:0001642
lung disorder2MONDO:0005275EFO:0003818
mast cell leukemia2MONDO:0020334EFO:0007359
tropical spastic paraparesis2MONDO:0008039EFO:0007527
B-cell prolymphocytic leukemia2MONDO:0019461EFO:1000102
T-cell prolymphocytic leukemia2MONDO:0019468EFO:1000560
Burkitt lymphoma2MONDO:0007243EFO:0000309
interstitial cystitis2MONDO:0018301EFO:0008507
myocarditis2MONDO:0004496EFO:0009609
myositis disease2MONDO:0021167EFO:0000783
lacrimal apparatus disorder2MONDO:0001854HP:0009926
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
kidney cancer2MONDO:0002367MONDO:0002367
ovarian cancer2MONDO:0008170MONDO:0008170
follicular lymphoma2MONDO:0018906MONDO:0018906
brain injury2MONDO:0043510MONDO:0043510
severe acute respiratory syndrome2MONDO:0005091EFO:0000694
ischemia reperfusion injury2MONDO:0005203EFO:0002687
myelodysplastic/myeloproliferative disease2MONDO:0020077MONDO:0020077
retinoblastoma2MONDO:0008380MONDO:0008380
familial lipoprotein lipase deficiency2MONDO:0009387MONDO:0009387
Leber hereditary optic neuropathy2MONDO:0010788MONDO:0010788
chronic granulomatous disease2MONDO:0018305MONDO:0018305
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
glaucoma2MONDO:0005041MONDO:0005041
plasma cell neoplasm2MONDO:0004959EFO:0000200
Tako-tsubo cardiomyopathy2MONDO:0019018EFO:1002000
renal artery obstruction2MONDO:0006945HP:0001920
chronic obstructive pulmonary disease1MONDO:0005002EFO:0000341
renal cell carcinoma1MONDO:0005086EFO:0000681
venous thromboembolism1MONDO:0005399EFO:0004286
urticaria1MONDO:0005492EFO:0005531
aspergillosis1MONDO:0005657EFO:0007157
beta thalassemia1MONDO:0019402Orphanet:848
brain neoplasm1MONDO:0021211EFO:0003833
Sezary syndrome1MONDO:0017844EFO:1000785
mycosis fungoides1MONDO:0009691EFO:1001051
uveitis1MONDO:0020283EFO:1001231
respiratory syncytial virus infectious disease1MONDO:0001577EFO:1001413
myeloproliferative neoplasm1MONDO:0020076EFO:0002428
neutropenia1MONDO:0001475MONDO:0001475
type 2 diabetes mellitus1MONDO:0005148MONDO:0005148
sickle cell disease1MONDO:0011382MONDO:0011382
DiGeorge syndrome1MONDO:0008564MONDO:0018923
osteogenesis imperfecta1MONDO:0019019MONDO:0019019
mucopolysaccharidosis1MONDO:0019249MONDO:0019249
Fanconi anemia1MONDO:0019391MONDO:0019391
hereditary angioedema1MONDO:0019623MONDO:0019623
neuroepithelial neoplasm0MONDO:0021193MONDO:0021193

18 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 642.

Phase distribution

PhaseTrials
PHASE2233
PHASE4105
PHASE395
PHASE177
Not specified62
PHASE1/PHASE248
PHASE2/PHASE316
EARLY_PHASE16

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04239859PHASE4NOT_YET_RECRUITINGOutcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis
NCT04537689PHASE4RECRUITINGOutcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
NCT05839314PHASE4RECRUITINGEffect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
NCT05867329PHASE4RECRUITINGFeasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
NCT06364319PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
NCT06424639PHASE4NOT_YET_RECRUITINGLuspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA
NCT06525948PHASE4NOT_YET_RECRUITINGEfficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA
NCT07352566PHASE4NOT_YET_RECRUITINGUtilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07368595PHASE4NOT_YET_RECRUITINGComparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks
NCT07381556PHASE4RECRUITINGCyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
NCT00048165PHASE4COMPLETEDA Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
NCT00087581PHASE4COMPLETEDStudy of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
NCT00118742PHASE4COMPLETEDLiver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
NCT00123331PHASE4COMPLETEDRapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation
NCT00139009PHASE4COMPLETEDIntracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation
NCT00139035PHASE4COMPLETEDEffects of Cyclosporine A on Pancreatic Insulin Secretion
NCT00149994PHASE4COMPLETEDCyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
NCT00150085PHASE4TERMINATEDSafety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion
NCT00154193PHASE4COMPLETEDNordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels
NCT00154310PHASE4COMPLETEDEfficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
NCT00159159PHASE4UNKNOWNLOW CYCLO: Study Evaluating the Benefit of Two Doses of Ciclosporine in de Novo Cardiac Transplant
NCT00160966PHASE4COMPLETEDImpact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy
NCT00163657PHASE4COMPLETEDStudy of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
NCT00166816PHASE4UNKNOWNThe Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients
NCT00166842PHASE4UNKNOWNSirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
NCT00171496PHASE4COMPLETEDEvaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients
NCT00171509PHASE4COMPLETEDEfficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
NCT00171743PHASE4COMPLETEDEfficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients
NCT00182559PHASE4COMPLETEDThe Vienna Prograf and Endothelial Progenitor Cell Study
NCT00195468PHASE4COMPLETEDStudy Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus
NCT00200551PHASE4COMPLETEDA Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant
NCT00209859PHASE4COMPLETEDMethotrexate and Cyclosporine in Treatment of Early Rheumatoid Arthritis
NCT00260208PHASE4TERMINATEDLiver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
NCT00264355PHASE4COMPLETEDMetabolic Pattern of Cyclosporine A and Acute Renal Failure
NCT00296296PHASE4COMPLETEDImmunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
NCT00348335PHASE4COMPLETEDEfficacy of Topical Cyclosporin for Ocular Rosacea
NCT00349440PHASE4COMPLETEDEfficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
NCT00349583PHASE4COMPLETEDEfficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation
NCT00383396PHASE4COMPLETEDEfficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia
NCT00399061PHASE4COMPLETEDEfficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

285 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CaspofunginChEMBL + PubChemPhase 4 (approved)ABCG2, SLC10A1, SLCO1B1, SLCO1B3
RITONAVIRChEMBL + PubChemPhase 4 (approved)ABCG2, SLC10A1, SLCO1B1, SLCO1B3
SULFASALAZINEChEMBLPhase 4 (approved)ABCG2, SLC10A1, SLCO1B1, SLCO1B3
ALISPORIVIRChEMBLPhase 3ABCG2, PPIA, SLCO1B1, SLCO1B3
chenodiolPubChemApprovedFPR1, SLC10A1, SLCO1B1, SLCO1B3
Deoxycholic AcidPubChemApprovedFPR1, SLC10A1, SLCO1B1, SLCO1B3
ATAZANAVIRChEMBL + PubChemPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
CANDESARTAN CILEXETILChEMBL + PubChemPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
ERLOTINIBChEMBL + PubChemPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
EzetimibeChEMBL + PubChemPhase 4 (approved)SLC10A1, SLCO1B1, SLCO1B3
RIFAMPINChEMBL + PubChemPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
VERAPAMILChEMBL + PubChemPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
ATORVASTATINChEMBLPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
ELTROMBOPAGChEMBLPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
LOSARTANChEMBLPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
TELMISARTANChEMBLPhase 4 (approved)ABCG2, SLCO1B1, SLCO1B3
FASIGLIFAMChEMBLPhase 3SLC10A1, SLCO1B1, SLCO1B3
GENISTEINChEMBLPhase 2ABCG2, SLCO1B1, SLCO1B3
BumetanidePubChemApprovedSLC10A1, SLCO1B1, SLCO1B3
Folic AcidPubChemApprovedABCG2, SLCO1B1, SLCO1B3
LinagliptinPubChemApprovedABCG2, SLCO1B1, SLCO1B3
MethotrexatePubChemApprovedABCG2, SLCO1B1, SLCO1B3
OlmesartanPubChemApprovedSLC10A1, SLCO1B1, SLCO1B3
EtravirineChEMBL + PubChemPhase 4 (approved)ABCG2, SLCO1B1
FUROSEMIDEChEMBL + PubChemPhase 4 (approved)ABCG2, SLC10A1
HYDROXYZINE PAMOATEChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
OLMESARTAN MEDOXOMILChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
PRAVASTATINChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
TANNIC ACIDChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
VINBLASTINEChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
BETA CAROTENEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
CARBENOXOLONEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
CLARITHROMYCINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
DICLOXACILLINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
DIGOXINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
ERYTHROMYCIN ESTOLATEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
ERYTHROMYCIN ETHYLSUCCINATEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
GEMFIBROZILChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
INDOMETHACINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
LANSOPRAZOLEChEMBLPhase 4 (approved)ABCG2, PPIA
MITOXANTRONEChEMBLPhase 4 (approved)ABCG2, SLCO1B3
MOMETASONE FUROATEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
NONOXYNOL 9ChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
PACLITAXELChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
RIFAMYCINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
SIROLIMUSChEMBLPhase 4 (approved)ABCG2, SLCO1B1
TACROLIMUSChEMBLPhase 4 (approved)ABCG2, SLCO1B1
TELITHROMYCINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
VINCRISTINEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
CURCUMINChEMBL + PubChemPhase 3 (approved)ABCG2, SLC10A1
ADMILPARANTChEMBLPhase 3SLCO1B1, SLCO1B3
GOSSYPOLChEMBLPhase 3SLCO1B1, SLCO1B3
PAMIPARIBChEMBLPhase 3SLCO1B1, SLCO1B3
SILIBININChEMBLPhase 3SLCO1B1, SLCO1B3
SILYBIN AChEMBLPhase 3SLCO1B1, SLCO1B3
GLYCYRRHIZINChEMBL + PubChemPhase 2 (approved)SLCO1B1, SLCO1B3
BMS-986020ChEMBLPhase 2SLCO1B1, SLCO1B3
CLESACOSTATChEMBLPhase 2ABCG2, SLCO1B1
ENOXOLONEChEMBLPhase 2SLCO1B1, SLCO1B3
SILICRISTINChEMBLPhase 2SLCO1B1, SLCO1B3

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot